Dr Jeffrey Bradstreet has now treated over 2,000 autistic children with GcMAF and the results are well established. In 15% GcMAF makes no difference. 85% improve, if only a little, and of them 15% have their autism eradicated. In all 3,000 children have been treated with GcMAF with similar results.

And Dr Bradstreet has published a paper: Initial Observations of Elevated Alpha-N-Acetylgalactosaminidase Activity Associated with Autism and Observed Reductions from GC Protein—Macrophage Activating Factor Injections which is ground breaking in its discoveries.

With Dr Bradstreet we ourselves published a groundbreaking paper in “Frontiers in Neurology” on the 2nd January 2014 where we identify, for the first time, the point in the human brain where autism resides.

In our opinion Autism tends to be caused by the MMR and other vaccines putting viruses and mercury into children. A shortage of lipids may contribute. Another Italian court has awarded €178,000 against the government to a family who’s child contracted autism from MMR.

These viruses sabotage the immune system by sending out nagalase to prevent the production of the child’s GcMAF, and therefore become chronic.

Autism is usually a viral disease to a greater or lesser extent, with viruses in the brain and the stomach. In 15% of children viruses are negligible, and GcMAF probably will not help. In 85% viruses are involved, and they will respond to GcMAF. In 15% of children autism is mainly a viral disease, and these children make full recoveries.

Children can begin to respond inside 5 weeks. If nothing happens in 16 weeks, their autism may not be viral. If they respond, GcMAF should be continued for typically 24 weeks, or 8 weeks after they appear to be recovered, to ensure the viruses does not return.

GcMAF has three excellent effects in the brain and rebuilds the immune system, which then attacks the viruses that cause autism. Improvements in the child are often seen as early as five weeks – about the same time it often takes to permanently eradicate the herpes virus.   We recommend a child starts at 0.03ml, with a second 0.03 dose in three days, to build up to a twice weekly 0.1ml dose as soon as possible. Make sure he eats plenty of lipids. But see Dr Antonucci’s recommendations below.

Children with autism often have very high levels of vitamin D3, occasionally toxic levels (and low levels of D2) which may be produced by gut bacteria. We do not recommend any change to vitamin D3 (which may result in severe hyperactivity) or any change to anything else, until you are four weeks in with the GcMAF. Even then, not unless the child has had a vitamin D level test. So change nothing else at the time you start GcMAF, or preferably Goleic.

In the last six months I’ve collected reports from 94 families that have tried GcMAF with their children affected by autism, and the results seem very encouraging.

The age of children ranges from 3 to 15 years old (except one who was 21). 83 of them reported significant improvements, 7 did not notice any change, while 4 showed side effects.

Using the of vial 2,2 ml  (100 ng/0,25 ml), they started to inject 0,01-0,02 ml (1-2 units of a insulin syringe 0,5 ml) and increasing every week by 1 unit until reaching a dosage of 8-25 units, depending on body weight and the individual response of each child.

Parents noticed the first improvements from just the first 2-3 weeks after treatment, and they continued to increase the dosage to the point where they did not notice further improvements and/or started to see some side effects such as hyperactivity, or defiant and negative behaviours.

We also observe there is not any specific correlation between weight and dosage; this means that children who weigh 20 kg could tolerate dosage up to 15-18 units; and boys who weigh more than 45 kg could show satisfactory improvements on a dosage not more than 7-8 units.

Some of the parents who noticed side effects with higher dosages tried, sometimes successfully, to keep up a maximum dosage if it could be tolerated, or if provoking only mild side effects for 2-3 weeks, and then tried again to increase it. In this way, they were able to control and avoid side effects and gain better improvements. This is reasonable, because those symptoms could be just the effect of the activation of the immune system. Then, once a new balance of the immune system is achieved, it could be possible to proceed to a further step up in activation.

The most common reported improvements concern cognitive abilities: attention and focus, learning and understanding, receptiveness and awareness of the environment and people around them, in addition receptive language (understanding new and complex sentences from parents and adults) and expressive language (ability to pronounce the first words, or increase the number of known words, or improve imitation, language and speech fluency), social skills (willing to interact and communicate with peers).
Finally, they also reported improvements in behaviour: less hyperactive, less stereotypical, more cooperative and compliant.
The 4 children who had side effects showed hyperactivity, increase of stimming, agitation and aggressiveness, even with low dosage, which completely disappeared after discontinuing GcMAF.
It’s interesting to notice that the children that already show aberrant behaviour can improve the same behaviour that seems to get worse in the children that show side effects.

Case 1
M. 6 yo, male, 30 kg. Dx of Autism. 15 units/week of GcMAF. 12 weeks of treatment.
More attentive and receptive. Increase in verbal imitation and appropriate spontaneous use of words, increase the vocabulary of words correctly used (from 2-3 words to 40 words). Better pronunciation and articulation of words. Increasing dosage showed rare episodes of aggression.
Case 2
R. 6 yo, 20kg, Dx of PPD of Autism Spectrum, 10 units/week of GcMAF for 20 weeks.
Much more cooperative and obedient, receptive, language now completely fluent, learning strongly improved. Aggression and negative behaviour completely disappeared.
Case 3
C. 15 yo, male 46 kg. Dx of Autism with OCD. 18 units in 24 weeks of treatment.
Significant reduction of obsessive-compulsive behaviour (nothing could be moved in room, or he could react with severe tantrums). Aggression completely disappeared.
Case 4
P. 7 aa, 25 kg, Dx of Autism. 17 units/week of GcMAF for 16 weeks of treatments.
Hyperactivity completely disappeared, increased focus and attention, increased cognitive function and learning, and able to follow the curricular subjects like his peers. Better pronunciation and articulation of words and sentences. More respectful of rules at  school and at home.
Case 5
F. 21 yo, 103 kg, Dx of Autism. 10 units/week of GcMAF, 10 weeks of treatment.
Severe awakening with loud screams and aggression lessened significantly until he awoke without agitation and aggression. Impulsive and aggression during the day completely disappeared. These improvements allowed the parents to discontinue psychotropic medications that he had been taking for many years.

NB: This report is not a prescription or a medical recommendation and I strongly invite you to ask your doctor about GcMAF or any medical treatment for Autism and Autism Spectrum Disorders. 1st June 2012

Dr Nicola Antonucci
MD from University of Bari, Italy in July 2000. Specialized in the same University in Psichiatry in January 2005. During the School of Specialization he was member of research of “Gruppo di Neuroscienze Psichiatriche” and worked on NeuroImaging Field using functional MRI and Spectroscopy  applied in patients affected by schizofrenia-.
Since October 2006, when his daughter was diagnosed ASD, he started to work with Biomedical Treatment of ASDs using the knowledge of Autism Research Institute – San Diego (CA). He followed medical training  for several months at the “The Rimland Centre – Lynchburg (VA)” under the mentoring of Dr E. Mumper. He is still attending annual scientific meeting and training of Autism Research Institute.
He is now director of the “Biomedical Centre for Autism Research and Treatment” in Bari – Italy and working in several towns of Italy, as well as in several Countries exclusively with children affected by ASDs. In 2010, in collaboration with Dr. Dario Siniscalco, Second University of Naples, he founded a research group to study molecular and cellular changes in ASDs. This group is conducting several research trials and has already published some works on international peer-reviewed journals in the field of Autism.

Dr. Dario Siniscalco
ChemD from University of Naples “Federico II”, Italy in March 2000. PhD in Pharmacological Sciences from Second University if Naples, Italy in December 2004. He completed his neuropathology fellowship at University of Alabama at Birmingham, USA before joining the Second University of Naples staff in 2006. He is registered member of the following scientific societies: Order of the Chemists of Campania, National Council for Chemistry, Stem Cell Research Italy, European Association for Chemical and Molecular Sciences, Italian Pharmacological Society and Cell Death Research Group – University of Alabama at Birmingham, USA. His field of research is concerning the use of human mesenchymal stem cells as therapeutic tool in neurodegeneration. He is author or co-author of 35 scientific peer-reviewed papers, 5 book chapters and presented his work to 80 national and international conferences. In 2010, with Dr. Nicola Antonucci, he founded a research group specifically dedicated to study molecular and cellular changes in ASDs. This group is conducting several research trials and has already published some works on international peer-reviewed journals in the field of Autism.